270 related articles for article (PubMed ID: 32932783)
21. [125I][Tyr3]octreotide labels human somatostatin sst2 and sst5 receptors.
Siehler S; Seuwen K; Hoyer D
Eur J Pharmacol; 1998 May; 348(2-3):311-20. PubMed ID: 9652348
[TBL] [Abstract][Full Text] [Related]
22. Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog
Sauter AW; Mansi R; Hassiepen U; Muller L; Panigada T; Wiehr S; Wild AM; Geistlich S; Béhé M; Rottenburger C; Wild D; Fani M
J Nucl Med; 2019 Mar; 60(3):393-399. PubMed ID: 30002107
[TBL] [Abstract][Full Text] [Related]
23. Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy.
Ben-Shlomo A; Schmid H; Wawrowsky K; Pichurin O; Hubina E; Chesnokova V; Liu NA; Culler M; Melmed S
J Clin Endocrinol Metab; 2009 Nov; 94(11):4342-50. PubMed ID: 19820006
[TBL] [Abstract][Full Text] [Related]
24. Differential effects of somatostatin and angiopeptin on cell proliferation.
Alderton F; Lauder H; Feniuk W; Fan TP; Humphrey PP
Br J Pharmacol; 1998 May; 124(2):323-30. PubMed ID: 9641549
[TBL] [Abstract][Full Text] [Related]
25. Association of somatostatin receptor 2 immunohistochemical expression with [111In]-DTPA octreotide scintigraphy and [68Ga]-DOTATOC PET/CT in neuroendocrine tumors.
Müssig K; Oksüz MO; Dudziak K; Ueberberg B; Wehrmann M; Horger M; Schulz S; Häring HU; Pfannenberg C; Bares R; Gallwitz B; Petersenn S
Horm Metab Res; 2010 Jul; 42(8):599-606. PubMed ID: 20422506
[TBL] [Abstract][Full Text] [Related]
26. Unexpected sensitivity of sst2 antagonists to N-terminal radiometal modifications.
Fani M; Braun F; Waser B; Beetschen K; Cescato R; Erchegyi J; Rivier JE; Weber WA; Maecke HR; Reubi JC
J Nucl Med; 2012 Sep; 53(9):1481-9. PubMed ID: 22851637
[TBL] [Abstract][Full Text] [Related]
27. Experience with indium-111 and yttrium-90-labeled somatostatin analogs.
Virgolini I; Traub T; Novotny C; Leimer M; Füger B; Li SR; Patri P; Pangerl T; Angelberger P; Raderer M; Burggasser G; Andreae F; Kurtaran A; Dudczak R
Curr Pharm Des; 2002; 8(20):1781-807. PubMed ID: 12171531
[TBL] [Abstract][Full Text] [Related]
28. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs.
de Jong M; Breeman WA; Valkema R; Bernard BF; Krenning EP
J Nucl Med; 2005 Jan; 46 Suppl 1():13S-7S. PubMed ID: 15653647
[TBL] [Abstract][Full Text] [Related]
29. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.
Kwekkeboom DJ; Mueller-Brand J; Paganelli G; Anthony LB; Pauwels S; Kvols LK; O'dorisio TM; Valkema R; Bodei L; Chinol M; Maecke HR; Krenning EP
J Nucl Med; 2005 Jan; 46 Suppl 1():62S-6S. PubMed ID: 15653653
[TBL] [Abstract][Full Text] [Related]
30. Metal-ion-dependent biological properties of a chelator-derived somatostatin analogue for tumour targeting.
Heppeler A; André JP; Buschmann I; Wang X; Reubi JC; Hennig M; Kaden TA; Maecke HR
Chemistry; 2008; 14(10):3026-34. PubMed ID: 18246556
[TBL] [Abstract][Full Text] [Related]
31.
Liu F; Zhu H; Yu J; Han X; Xie Q; Liu T; Xia C; Li N; Yang Z
Tumour Biol; 2017 Jun; 39(6):1010428317705519. PubMed ID: 28618966
[TBL] [Abstract][Full Text] [Related]
32. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP
Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
[TBL] [Abstract][Full Text] [Related]
33. Characterization of somatostatin receptor subtype 2 expression in stably transfected A-427 human cancer cells.
Parry JJ; Eiblmaier M; Andrews R; Meyer LA; Higashikubo R; Anderson CJ; Rogers BE
Mol Imaging; 2007; 6(1):56-67. PubMed ID: 17311765
[TBL] [Abstract][Full Text] [Related]
34. Somatostatin receptor expression and patients' response to targeted medical treatment in pituitary tumors: evidences and controversies.
Gatto F; Arvigo M; Ferone D
J Endocrinol Invest; 2020 Nov; 43(11):1543-1553. PubMed ID: 32557353
[TBL] [Abstract][Full Text] [Related]
35. Peptide receptor radionuclide therapy with somatostatin analogues in neuroendocrine tumors.
Giovacchini G; Nicolas G; Forrer F
Anticancer Agents Med Chem; 2012 Jun; 12(5):526-42. PubMed ID: 22292758
[TBL] [Abstract][Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]